LOUISVILLE, CO -- (MARKET WIRE) -- October 17, 2006 -- GlobeImmune, Inc. announced today that the interim results from a placebo-controlled Phase 1b study of GI-5005 in patients chronically infected with hepatitis C virus will be presented at the 57th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) on Monday, October 30 in the Late Breaking Poster session. Full abstracts can now be viewed at the AASLD website at http://www.aasld.org.
